An MPO inhibitor (IC50 = 0.3 µM); reduces opsonized zymosan- or PMA-induced HOCl production in isolated human neutrophils (IC50s = 16 and 2.2 µM, respectively); inhibits PMA-induced NET formation in the same cells; reduces infarct volume and the severity of neurological deficits, as well as increases survival, in a mouse model of transient MCAO-induced cerebral ischemia at 40 mg/kg twice per day